secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0000950170-23-056048
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Appoints Michael King as CFO with $450K salary and 850K share option grant
--------------------------------------------------------------------------

- Michael King appointed CFO effective Oct 30, 2023; Russell Beyer ceased as CFO on Oct 27.
- Base salary $450,000, target annual bonus of 40% of base, and 850,000 stock options.
- Options vest over 4 years: 25% on 1-year anniversary, then monthly over 36 months.
- King has 25+ years in biotech research; most recently Co-Head of Healthcare at EF Hutton.
- No family relationships or arrangements with others influenced his selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/sabs-20231023.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer